Despite being a world leader in the supply of medical radioisotopes, Europe relies heavily on third countries for key source materials and specific processing operations. This has the potential to disrupt supply chains and threaten access to life-saving diagnosis and treatment for many Europeans. To reverse this trend and meet the increasing demand from patients, we need public and private investment in research and development and in new production infrastructure, sound regulation and bold political decisions, writes rapporteur of the EESC opinion on the supply of medical radioisotopes, Alena Mastantuono.